Cubresa

Cubresa We help reveal disease & therapeutic mechanisms with instruments that enable simultaneous molecular

We help reveal disease & therapeutic mechanisms with instruments that enable simultaneous molecular & functional imaging.

04/13/2026

We are proud to announce that Cubresa Inc. has signed a Letter of Intent (LOI) with The University of Edinburgh. This LOI is the first step towards a Collaboration Agreement focused on the development of a Pre-Clinical Therapeutic Road Map for Scaling Neurodegenerative Disease Interventions.

Areas of interest include:
- Precision Validation: Utilizing advanced molecular imaging to verify therapeutic efficacy earlier in the development cycle.

- Scalable Frameworks: Creating standardized protocols that allow promising interventions to move toward clinical trials with greater speed and reliability.

- Global Impact: Addressing the urgent need for scalable treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative conditions.

Cubresa is incredibly proud to collaborate with the University of Edinburgh - and to push the boundaries of what’s possible in brain health!

03/11/2026

Cubresa Inc. is pleased to announce the signing of a Master Research Agreement (MRA) with Lawson Health Research Institute.

This agreement is an expansion of a 10-year research partnership with Lawson and marks a new era of collaboration in brain-focused pre-clinical and clinical research. Future projects will focus on advanced BrainPET imaging, streamlining the path from pre-clinical research discoveries into clinical environments where they can impact patient lives.

We are incredibly proud of what we have achieved together over the last decade and look forward to many more years of innovation and collaborative success with the Lawson team!

01/13/2026

Cubresa Files First FDA 510(k) Application

Cubresa Inc. is pleased to announce the company has submitted the Cubresa BrainPET™ 510(k) Premarket Notification to the Food and Drug Administration (FDA)

This submission marks a pivotal step in our company’s mission to bring world-class brain imaging technology into clinical settings,” remarked James Schellenberg, Cubresa’s Founder and CEO, “by seeking FDA clearance for our BrainPET technology, we are moving one step closer to providing clinicians with high performing, cost-effective, simultaneous PET/MRI imaging to assist in the diagnosis and monitoring of a broad spectrum of brain diseases.”

A huge thank you to our incredible team, partners, and investors who help Cubresa reach this milestone.



Forward Looking Statements
This release contains certain forward-looking statements regarding Cubresa's 510(k) premarket notification to the FDA for the BrainPET™ System. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, and there can be no assurance that Cubresa will obtain 510(k) clearance from the FDA for the BrainPET™ System or as to the timing of any such clearance. Many of these risks and uncertainties are beyond the company's control, including without limitation, risks relating to regulatory clearance and market acceptance of the System.

Address

300 – 136 Market Avenue
Winnipeg, MB
R3B0P4

Opening Hours

Monday 8am - 5:30pm
Tuesday 8am - 5:30pm
Wednesday 8am - 5:30pm
Thursday 8am - 5:30pm
Friday 8am - 5:30pm

Website

Alerts

Be the first to know and let us send you an email when Cubresa posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Cubresa:

Shortcuts

Share

Category